{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:11:34Z","timestamp":1794370294873,"version":"4.9.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.semarthrit.2023.152231","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T21:57:11Z","timestamp":1686261431000},"page":"152231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Risk factors for mortality in patients with anti-MDA5 antibody-positive dermatomyositis: A meta-analysis and systematic review"],"prefix":"10.1016","volume":"62","author":[{"given":"Huaiya","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingding","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junping","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.semarthrit.2023.152231_bib0001","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152231_bib0002","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.chest.2020.04.057","article-title":"Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR model","volume":"158","author":"Lian","year":"2020","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152231_bib0003","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152231_bib0004","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology (United Kingdom)"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152231_bib0005","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s10067-007-0562-9","article-title":"Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study","volume":"26","author":"Ye","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152231_bib0006","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","article-title":"The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM","volume":"51","author":"Koga","year":"2012","journal-title":"Rheumatology (United Kingdom)"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152231_bib0007","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/acr.21985","article-title":"Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis","volume":"65","author":"Chen","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2023.152231_bib0008","doi-asserted-by":"crossref","DOI":"10.1007\/s12016-020-08822-5","article-title":"Interstitial lung disease in anti-MDA5 positive dermatomyositis","author":"Wu","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152231_bib0009","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1241\/johokanri.54.254","article-title":"Practice guideline of evidence-based medicine: preferred reporting items for systematic reviews and meta-analyses (the PRISMA statement)","volume":"54","author":"Taku","year":"2011","journal-title":"J Inf Process Manag"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152231_bib0010","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/rheumatology\/keab305","article-title":"Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study","volume":"61","author":"Wu","year":"2022","journal-title":"Rheumatology (United Kingdom)"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152231_bib0011","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","article-title":"Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152231_bib0012","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s10067-019-04457-w","article-title":"Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody","volume":"38","author":"Jiang","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152231_bib0013","first-page":"5046","article-title":"Predictive factors for mortality in anti-melanoma-associated gene 5 antibody-associated interstitial lung disease","volume":"71","author":"Gono","year":"2019","journal-title":"Arthrit Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152231_bib0014","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3899\/jrheum.180825","article-title":"Clinical significance of serum chitotriosidase level in Anti-MDA5 antibody\u2013positive dermatomyositis-associated interstitial lung disease","volume":"46","author":"Fujisawa","year":"2019","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152231_bib0015","doi-asserted-by":"crossref","first-page":"e22978","DOI":"10.1002\/jcla.22978","article-title":"Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease","volume":"33","author":"Ye","year":"2019","journal-title":"J Clin Lab Anal"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152231_bib0016","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/rheumatology\/kez185","article-title":"Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD","volume":"58","author":"Horiike","year":"2019","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1016\/j.semarthrit.2023.152231_bib0017","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez065","article-title":"Serum matrix metalloproteinase levels in polymyositis\/dermatomyositis patients with interstitial lung disease","author":"Nakatsuka","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2023.152231_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105983","article-title":"Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis \/dermatomyositis associated ILD","volume":"172","author":"Mao","year":"2020","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152231_bib0019","first-page":"1068","article-title":"Surfactant protein D is associated with 3-month mortality of anti-MDA5 antibody-interstitial lung disease","volume":"38","author":"Lyu","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152231_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155209","article-title":"Prognostic evaluation of serum osteopontin in patients with anti-MDA5 antibody-positive dermatomyositis associated interstitial lung disease","volume":"135","author":"Gao","year":"2020","journal-title":"Cytokine"},{"issue":"22","key":"10.1016\/j.semarthrit.2023.152231_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10225241","article-title":"Gap score and ca-153 associated with one-year mortality in anti-mda-5 antibody-positive patients: a real-world experience","volume":"10","author":"Tseng","year":"2021","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152231_bib0022","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/art.41566","article-title":"Risk prediction modeling based on a combination of initial serum biomarker levels in polymyositis\/dermatomyositis\u2013associated interstitial lung disease","volume":"73","author":"Gono","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152231_bib0023","article-title":"A computed tomography radiomics-based prediction model on interstitial lung disease in Anti-MDA5-positive dermatomyositis","volume":"8","author":"Xu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.semarthrit.2023.152231_bib0024","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaa843","article-title":"Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis","author":"Gui","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2023.152231_bib0025","first-page":"1","article-title":"Prognostic value of peripheral blood markers in patients with myositis-associated interstitial lung diseases","author":"Jin","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152231_bib0026","volume":"8","author":"Wang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.semarthrit.2023.152231_bib0027","article-title":"Time-dependent changes in RPILD and mortality risk in anti-MDA5+ DM patients: a cohort study of 272 cases in China","author":"You","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2023.152231_bib0028","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keac094","article-title":"Predictors of rapidly progressive- interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis","author":"So","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152231_bib0029","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s10067-021-06033-7","article-title":"Quantitative CT analysis of interstitial pneumonia in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a single center, retrospective study","volume":"41","author":"Yamaguchi","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.semarthrit.2023.152231_bib0030","article-title":"A New Predictive Model for the Prognosis of MDA5(+) DM-ILD","volume":"9","author":"Niu","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152231_bib0031","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/mr\/roab017","article-title":"Clinical significance of HScore and MS score comparison in the prognostic evaluation of anti-MDA5-positive patients with dermatomyositis and interstitial lung disease","volume":"32","author":"Zhao","year":"2022","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152231_bib0032","article-title":"Differences in sex- and age-associated mortality in patients with anti-MDA5 positive dermatomyositis","author":"He","year":"2022","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152231_bib0033","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12890-022-02106-8","article-title":"Neutrophil-to-lymphocyte ratio is a predictive marker for anti-MDA5 positive dermatomyositis","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.semarthrit.2023.152231_bib0034","article-title":"The long-term outcome and prognosis factor of patients with idiopathic inflammatory myopathies based on myositis-specific autoantibodies","author":"Jiang","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152231_bib0035","doi-asserted-by":"crossref","first-page":"292","DOI":"10.55563\/clinexprheumatol\/zmn18h","article-title":"Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease","volume":"40","author":"Zhu","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152231_bib0036","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/mr\/roab006","article-title":"Chest computed tomography findings of adult patients with antimelanoma differentiation-associated protein 5 antibody-positive interstitial lung disease","volume":"32","author":"Waseda","year":"2022","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152231_bib0037","article-title":"A matrix prediction model for the 6-month mortality risk in patients with anti-melanoma differentiation-associated protein-5-positive dermatomyositis","volume":"9","author":"Ouyang","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152231_bib0038","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.semarthrit.2020.03.007","article-title":"Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease","volume":"50","author":"Romero-Bueno","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152231_bib0039","article-title":"The impact of aging in acute respiratory distress syndrome: a clinical and mechanistic overview","volume":"7","author":"Brown","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152231_bib0040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14397595.2020.1740400","article-title":"Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age","volume":"31","author":"Yamaguchi","year":"2021","journal-title":"Mod Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152231_bib0041","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00296-017-3729-y","article-title":"Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody","volume":"37","author":"Isoda","year":"2017","journal-title":"Rheumatol. Int."},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152231_bib0042","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jaad.2017.12.010","article-title":"Anti-melanoma differentiation\u2013associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features","volume":"78","author":"Kurtzman","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.semarthrit.2023.152231_bib0043","article-title":"Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future","author":"Wang","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152231_bib0044","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3109\/14397595.2013.844390","article-title":"Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease","volume":"24","author":"Nara","year":"2014","journal-title":"Mod Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152231_bib0045","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10067-012-2142-x","article-title":"Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"32","author":"Muro","year":"2013","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152231_bib0046","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/joim.13154","article-title":"IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis\/dermatomyositis","volume":"289","author":"Shimizu","year":"2021","journal-title":"J Intern Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152231_bib0047","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12890-015-0154-4","article-title":"Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?","volume":"15","author":"Ikeda","year":"2015","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.semarthrit.2023.152231_bib0048","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.220367","article-title":"A Retrospective Analysis of Outcome in MDA5-Related Interstitial Lung Disease Treated with Tofacitinib or Tacrolimus","author":"Fan","year":"2022","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152231_bib0049","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: a Meta-analysis","volume":"326","author":"WHOREAfC-TW","year":"2021","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152231_bib0050","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1093\/rheumatology\/keaa906","article-title":"Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis","volume":"60","author":"Zhang","year":"2021","journal-title":"Rheumatology (Oxford)"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223000732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223000732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:09:56Z","timestamp":1758733796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017223000732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":50,"alternative-id":["S0049017223000732"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152231","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors for mortality in patients with anti-MDA5 antibody-positive dermatomyositis: A meta-analysis and systematic review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152231","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152231"}}